Open AccessFollicular Lymphoma Presenting With Monoclonal IgM And MYD88 Mutation: A Case Report And Review Of The Literature
Author(s) -
Lijun Xu,
Xiaoxiao Ding,
Limei Ying,
Xiaochang Zhang,
Nina Lu
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s211436
Subject(s) - follicular lymphoma , lymphoma , lymphoplasmacytic lymphoma , bortezomib , medicine , germline mutation , monoclonal , mutation , rituximab , waldenstrom macroglobulinemia , cancer research , oncology , pathology , immunology , monoclonal antibody , biology , multiple myeloma , antibody , genetics , gene
MYD88 mutation has been reported in various lymphomas, specifically in lymphoplasmacytic lymphoma. Yet, the mutation has not been reported in primary follicular lymphoma. Here, we present a 62-year-old male with follicular lymphoma who had an MYD88 L265P somatic mutation and monoclonal IgM gammopathy. He received four cycles of R-CHOP immunochemotherapy. Interim PET/CT evaluation indicated a state of stable disease (SD). Neither did serum IgM remarkably drop. He was then given a bortezomib-contained regimen which significantly reduced the level of serum IgM. To the best of our knowledge, this is the first report of follicular lymphoma with monoclonal IgM and MYD88 L265P mutation. The present case indicated bortezomib may benefit these patients.